Impella heart pump upgraded to Class 2a in ACC/AHA treatment guideline for cardiogenic shock secondary to STEMI

Median overall survival not yet reached with projected improvement of more than one year versus osimertinib

Oral presentation features new data from the 24-week pivotal Vivacity-MG3 study which show sustained disease control through treatment with nipocalimab on the clinician-assessed QMGa score in antibody positive adult patients: anti-AChR+, anti-MuSK+, anti-LRP4+ Nipocalimab data demonstrate longer-term sustained disease control as measured by MG-ADLb and QMG scores from the ongoing open-label extension (OLE) of the Vivacity-MG3 study Johnson & Johnson filed a Biologics License Application (BLA) for nipocalimab in August 2024 and was granted U.S. FDA Priority Review for the treatment of gMG Real-world studies highlight the unmet need of patients living with gMG, including those who are pregnant or receiving steroids

The DUALTO™ electrosurgical generator is designed to offer a simplified user experience, access to Polyphonic™ Fleet digital device management, and flexible application of monopolar, bipolar, ultrasonic, and advanced bipolar energy devices for open and minimally invasive surgery DUALTO will be showcased at the Association of periOperative Registered Nurses Global Surgical Conference & Expo on April 5-8, 2025 The DUALTO Energy System recently received 510(k) clearance by the U.S. Food & Drug Administration1

Investment builds on almost 140-year legacy of improving and saving lives and supporting American jobs Includes four planned new manufacturing facilities, with ground-breaking today in North Carolina on $2 billion+ facility Total Company U.S. economic impact estimated to be more than $100 billion per year

•New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases •Delivering on Company’s plans for increased U.S. investment, $2 billion+ advanced biologics facility will add more than 5,000 high-wage manufacturing and construction jobs in North Carolina. •Investment will create an estimated economic impact of $3 billion statewide during first 10 years of site operation

TREMFYA® is the only IL-23i to demonstrate clinical remission and endoscopic response, both at one year, with a fully subcutaneous induction regimen Supported by data from the GALAXI study, TREMFYA® is the only IL-23i to show superiority versus STELARA® in all pooled endoscopic endpoints within a double-blinded registrational trial TREMFYA® approval in Crohn’s disease builds upon recent ulcerative colitis FDA approval, marking the fourth indication for this dual-acting IL-23i in the U.S.

Median overall survival improvement projected to exceed one year with much-anticipated overall survival analysis showing statistically superior result versus osimertinib Preventative dermatologic regimen meets primary endpoint and enhances patient experience

Sjögren’s disease (SjD) is a prevalent, debilitating autoantibody disease with no FDA-approved advanced treatments The Company is actively enrolling patients in the Phase 3 DAFFODIL study This marks the fourth nipocalimab FDA Fast Track designation

Next-generation NVIDIA-powered AI navigation software elevates MONARCHTM Platform for Robotically Assisted Bronchoscopy